ProCE Banner Activity

Overview of Immunotherapy for Early-Stage NSCLC and Clinical Factors Influencing Response to Checkpoint Inhibition

Slideset Download

Download these slides from a live CCO Webinar for an overview of the evolving immunotherapy landscape for early-stage NSCLC along with coverage on how cachexia, immune-related adverse events, and disparities in care impact outcomes for patients with NSCLC receiving checkpoint inhibitor therapy.

Released: June 24, 2021

Expiration: June 23, 2022

No longer available for credit.

Share

Faculty

Joan McTigue

Joan McTigue, MS, PA-C

Physician Assistant
Division of Rheumatology
University of Florida College of Medicine
Gainesville, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Helsinn Healthcare SA

Regeneron Pharmaceuticals, Inc.

Sanofi Genzyme